目的 探讨MRI联合糖类抗原 125(CA125)及糖类抗原199(CA199)对Ⅰ期 上皮性卵巢癌的临床诊断价值。方法 选 择经病理切片证实的Ⅰ期上皮性卵巢癌患 者49例为观察组，42例妇科良性疾病患者 为良性组，53例健康体检者作为对照组， 对三组被研究者的MRI资料与血清检测中 CA125、CA199含量进行比较分析。结果 对照组、良性组及观察组患者体内CA125 血清因子含量比较，差异具有统计学意义 (F=33.630，P＜0.05)；三组中CA199血 清因子含量比较，差异具有统计学意义 (F=28.017，P＜0.05)。与单独指标检测 阳性率相比，联合CA125与CA199阳性检出 率显著提高(P＜0.05)，联合MRI与血清因 子CA125、CA199含量变化阳性检出率显著 提高(P＜0.05)。与单独指标检测灵敏度 相比，联合CA125及CA199、联合MRI与血 清因子CA125、CA199，灵敏度均升高。结 论 MRI与血清因子CA125、CA199联合检测 Ⅰ期上皮性卵巢癌患者的阳性率提高，有 利于提高Ⅰ期上皮性卵巢癌患者的临床诊 出率。

Objective To explore the clinical diagnostic value of MRI combined with carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199) in the diagnosis of stage I epithelial ovarian cancer. Methods A total of 49 cases of patients with stage I epithelial ovarian cancer confirmed by pathological section were selected as observation group, and 42 cases were benign gynecological diseases and were selected as benign group, and 53 healthy examiners were included into control group. MRI data and serum contents of CA125 and CA199 were compared and analyzed in the three groups. Results There was a statistically significant difference in the serum CA125 level among control group, benign group and observation group (F=33.630, P<0.05). There was a statistically significant difference in the serum level of CA199 in the three groups (F=28.017, P <0.05). Compared with the positive detection rate of individual indicators, the positive detection rate of combined CA125 and CA199 was significantly increased (P<0.05), and the positive detection rate of combined MRI and serum factors CA125 and CA199 was significantly increased (P<0.05). Compared with the sensitivity of individual indicators, the sensitivities of combined CA125 and CA199, and combined MRI and serum factors CA125 and CA199 were increased. Conclusion The positive rate of MRI combined with serum factors CA125 and CA199 is increased in the detection of stage I epithelial ovarian cancer, which is beneficial to improve the clinical diagnosis rate of patients with stage I epithelial ovarian cancer.